Integra LifeSciences Holdings Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 2/6
Integra LifeSciences Holdings hat ein Gesamteigenkapital von $1.5B und eine Gesamtverschuldung von $1.8B, wodurch sich der Verschuldungsgrad auf 118.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $4.1B bzw. $2.5B. Integra LifeSciences Holdings Das EBIT des Unternehmens beträgt $193.9M, so dass der Zinsdeckungsgrad 4.2 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $277.6M.
Wichtige Informationen
118.9%
Verhältnis von Schulden zu Eigenkapital
US$1.81b
Verschuldung
| Zinsdeckungsgrad | 4.2x |
| Bargeld | US$277.60m |
| Eigenkapital | US$1.52b |
| Gesamtverbindlichkeiten | US$2.54b |
| Gesamtvermögen | US$4.07b |
Jüngste Berichte zur Finanzlage
Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?
Aug 21
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05Recent updates
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise
Nov 05Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Oct 24Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S
Sep 08Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?
Aug 21At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?
Jul 01Integra LifeSciences Still Underperforming As Manufacturing Issues Linger
Jun 21Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price
May 28Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled
Feb 27We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jan 14Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings
Dec 31Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?
Dec 03Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns
Oct 24Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 22Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?
Feb 27Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Feb 02We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return
Dec 21When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Dec 08Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: IARTDie kurzfristigen Aktiva des Unternehmens ($1.1B) übersteigen seine kurzfristigen Passiva ($912.6M).
Langfristige Verbindlichkeiten: IARTDie kurzfristigen Vermögenswerte des Unternehmens ($1.1B) decken seine langfristigen Verbindlichkeiten ($1.6B) nicht.
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: IARTDie Nettoverschuldung im Verhältnis zum Eigenkapital (100.6%) wird als hoch angesehen.
Schulden abbauen: IARTDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 107.3% auf 118.9% gestiegen.
Schuldendeckung: IARTDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (7.6%) gedeckt.
Zinsdeckung: IARTDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (4.2x Coverage) gut gedeckt.